Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 27 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Gland Pharma Ltd

About the Company - Gland Pharma Ltd

Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4400.71 Cr. and Equity Capital is Rs. 16.43 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSy.No. 143-148, 150 & 151, Hyderabad Telangana 500043investors@glandpharma.com
https://www.glandpharma.com
Management
NamePosition Held
Mr. Yiu Kwan Stanley LauChairman & Ind.Director
Mr. Srinivas SaduManaging Director & CEO
Mr. Qiyu ChenNon Executive Director
Mr. Yao FangNon Executive Director
Dr. Jia Ai (Allen) ZhangNon Executive Director
Mr. Udo Johannes VetterIndependent Director
Mr. Satyanarayana Murthy ChavaliIndependent Director
Mr. Essaji Goolam VahanvatiIndependent Director

Gland Pharma Ltd. Share Price Update

Share PriceValue
Today₹1,998.30
Previous Day₹1,989.35

Basic Stock Data of Gland Pharma Ltd

Market Cap 30,057 Cr.
Current Price 1,825
High / Low2,196/861
Stock P/E36.0
Book Value 510
Dividend Yield0.00 %
ROCE14.7 %
ROE10.8 %
Face Value 1.00

Data Source: screener.in

Gland Pharma Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales8328598881,1541,0801,0631,1038571,0489267858841,011
Expenses534595560718704714755587753642616625664
Operating Profit298264328436377349348270295284169259347
OPM %36%31%37%38%35%33%32%32%28%31%22%29%34%
Other Income20354762514665746662-183541
Interest1111112123221
Depreciation25252525262831353738383940
Profit before tax293273349472401366381309322305112254347
Tax %25%25%25%26%25%25%25%26%26%25%29%26%26%
Net Profit21920426035130227328622924022879188258
EPS in Rs14.1212.5015.9221.4018.4016.6417.4113.9414.5513.824.8111.3915.64

Gland Pharma Ltd Quarterly Chart

Gland Pharma Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales5277559919941,3481,4791,6202,0442,6333,4634,4013,6173,606
Expenses3945196306788458541,0851,3381,6782,1612,8902,5982,546
Operating Profit1332363613165026255357069551,3021,5111,0191,060
OPM %25%31%36%32%37%42%33%35%36%38%34%28%29%
Other Income14593037344966139135224184120
Interest31313171664473577
Depreciation11152857637478829599110147154
Profit before tax1332133272724595785026869931,3351,6191,0481,018
Tax %24%26%32%23%32%28%36%34%22%25%25%26%
Net Profit1011582242093144143214527739971,212776752
EPS in Rs86.09134.45190.40133.53202.40267.01207.24291.6549.8860.9473.7847.1145.66
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Gland Pharma Ltd Profit & Loss Yearly Chart

Gland Pharma Ltd Growth

Compounded Sales Growth
10 Years:17%
5 Years:17%
3 Years:11%
TTM:-11%
Compounded Profit Growth
10 Years:18%
5 Years:20%
3 Years:2%
TTM:-24%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:-4%
1 Year:53%
Return on Equity
10 Years:18%
5 Years:17%
3 Years:16%
Last Year:11%

Gland Pharma Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital12121216151616161616161616
Reserves4405988221,3791,6622,0742,3952,8473,6315,8877,1427,9378,382
Borrowings8412317616611766555544
Other Liabilities182187277197292378512655435588671815693
Total Liabilities7189201,2871,7582,0862,4742,9283,5234,0866,4967,8348,7739,095
Fixed Assets2063094606497888728439299689541,5021,5711,550
CWIP143202208192202161199123188338191177243
Investments000000000116381,891
Other Assets3694096199171,0961,4411,8872,4712,9295,2035,9787,0175,410
Total Assets7189201,2871,7582,0862,4742,9283,5234,0866,4967,8348,7739,095

Gland Pharma Ltd Reserves and Borrowings Chart

Gland Pharma Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 220476202185701605791368
Cash from Investing Activity -12-100-359-319-761-1,521-1,0071,211
Cash from Financing Activity -93-116-4-3-71,2383515
Net Cash Flow115260-160-136-67322-1811,594

Gland Pharma Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days64626262951031079083718987
Inventory Days230169229283248271283388250312205421
Days Payable6857745860136161190829780128
Cash Conversion Cycle225174217288283239229289251286214381
Working Capital Days8470100141155154185191161169168241
ROCE %29%36%39%22%28%30%22%27%30%28%25%15%

Gland Pharma Ltd Financial Efficiency Indicators Chart

Gland Pharma Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters58.36%58.25%58.14%58.02%58.00%58.00%57.87%57.86%57.86%57.86%57.86%57.86%
FIIs12.73%11.87%10.44%11.01%11.30%10.72%9.41%6.10%4.67%4.33%2.80%4.91%
DIIs10.81%11.25%12.10%11.75%11.66%12.46%17.36%21.92%23.13%23.23%23.38%22.45%
Public18.10%18.63%19.32%19.21%19.05%18.82%15.35%14.13%14.35%14.59%15.97%14.78%
No. of Shareholders77,26384,46798,2031,09,3261,09,0971,09,0981,17,3391,27,8791,48,4691,50,5781,81,7471,61,627

Gland Pharma Ltd Shareholding Pattern Chart

No. of Gland Pharma Ltd Shareholders

Gland Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Mirae Asset Emerging Bluechip Fund32712281.8505.73
Mirae Asset Large Cap Fund23379061.05361.44
Mirae Asset Tax Saver Fund20471141.81316.48
SBI Large & Midcap Fund20000001.98309.2
Nippon India Small Cap Fund16969330.7262.35
Mirae Asset Focused Fund15803112.82244.32
Nippon India Pharma Fund15000004.19231.9
Nippon India Multi Cap Fund14164371.05218.98
SBI Magnum Global Fund13000003.28200.98
HDFC Large and Mid Cap Fund - Regular Plan11058001.44170.96

Gland Pharma Ltd ROCE Trend

Gland Pharma Ltd EPS Trend

Gland Pharma Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20
FaceValue1.001.001.001.00
Basic EPS (Rs.)47.4473.8163.0749.88
Diluted EPS (Rs.)47.4373.8162.9949.88
Cash EPS (Rs.)56.3380.4666.9855.98
Book Value[Excl.RevalReserv]/Share (Rs.)483.23435.64360.86235.32
Book Value[Incl.RevalReserv]/Share (Rs.)483.23435.64360.86235.32
Revenue From Operations / Share (Rs.)220.07267.85211.68169.94
PBDIT / Share (Rs.)76.82105.5487.8470.64
PBIT / Share (Rs.)67.9198.8381.8064.54
PBT / Share (Rs.)64.0398.5181.5964.08
Net Profit / Share (Rs.)47.4273.7560.9449.88
NP After MI And SOA / Share (Rs.)47.4273.7560.9449.88
PBDIT Margin (%)34.9039.4041.4941.56
PBIT Margin (%)30.8536.8938.6437.97
PBT Margin (%)29.0936.7738.5437.70
Net Profit Margin (%)21.5427.5328.7929.35
NP After MI And SOA Margin (%)21.5427.5328.7929.35
Return on Networth / Equity (%)9.8116.9216.8821.19
Return on Capital Employeed (%)13.8922.3922.3626.83
Return On Assets (%)8.8915.4615.3418.91
Asset Turnover Ratio (%)0.430.610.650.00
Current Ratio (X)9.4610.0510.007.93
Quick Ratio (X)6.808.027.515.82
Inventory Turnover Ratio (X)1.101.661.720.00
Interest Coverage Ratio (X)169.90330.81421.28152.41
Interest Coverage Ratio (Post Tax) (X)113.46232.15293.28108.61
Enterprise Value (Cr.)17126.9950622.6337532.510.00
EV / Net Operating Revenue (X)4.7311.5010.840.00
EV / EBITDA (X)13.5429.1926.120.00
MarketCap / Net Operating Revenue (X)5.7612.2111.710.00
Price / BV (X)2.637.506.870.00
Price / Net Operating Revenue (X)5.7612.2111.710.00
EarningsYield0.030.020.020.00

Gland Pharma Ltd Profitability Ratios (%)

Gland Pharma Ltd Liquidity Ratios

Gland Pharma Ltd Liquidity Ratios (%)

Gland Pharma Ltd Interest Coverage Ratios (%)

Gland Pharma Ltd Valuation Ratios

Fair Value of Gland Pharma Ltd Stock

Fair Value: ₹2022.54

The stock is undervalued by 10.82% compared to the current price ₹1825

*Investments are subject to market risks

Strength and Weakness of Gland Pharma Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 27.58%, which is a positive sign.
  2. The company has higher reserves (3,476.62 cr) compared to borrowings (54.31 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (252.85 cr) and profit (320.54 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 78.27 and average Dividend Yield of 36.09%.
  2. The stock has a high average Working Capital Days of 151.58, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 256.33, which may not be favorable.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gland Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE